Literature DB >> 32651859

Multimodal evaluation of the cerebrovascular reserve in Neurofibromatosis type 1 patients with Moyamoya syndrome.

Alessandra D'Amico1, Lorenzo Ugga1, Sirio Cocozza2, Sara Maria Delle Acque Giorgio1, Domenico Cicala3, Claudia Santoro4, Daniela Melis5, Giuseppe Cinalli3, Arturo Brunetti1, Sabina Pappatà6.   

Abstract

PURPOSE: Moyamoya syndrome (MMS) is a rare intracranial arterial vasculopathy which can occur in neurofibromatosis type 1 (NF1) disease, representing a cause of cerebrovascular reserve (CVR) impairment, possibly leading to ischemic stroke. Here, we evaluated noninvasive imaging techniques used to assess CVR in MMS patients, describing clinical and imaging findings in patients affected by MMS-NF1.
METHODS: Following strict inclusion and exclusion criteria, in this retrospective observational study, we evaluated imaging data of nine consecutive MMS-NF1 patients (M/F = 5/4, mean age: 12.6 ± 4.0). Subjects underwent a multimodal evaluation of cerebral vascular status, including intracranial arterial MR Angiography (MRA), MRI perfusion with dynamic susceptibility contrast (DSC) technique, and 99mTc-hexamethylpropyleneamine oxime (HMPAO) SPECT.
RESULTS: In 8 out 9 patients (88.8%, 6/8 symptomatic), time-to-peak maps were correlated with the involved cerebral hemisphere, while in 6 out 9 patients (66.6%, 5/6 symptomatic), mean transit time (MTT) maps showed correspondence with the affected cerebrovascular territories. Cerebral blood flow (CBF) calculated using DSC perfusion failed to detect the hypoperfused regions instead identified by SPECT-CBF in all patients, while MTT maps overlapped with SPECT-CBF data in all cases and time-to-peak maps in 60.0%.
CONCLUSIONS: Although SPECT imaging still represents the gold standard for CBF assessment, our results suggest that data obtained using DSC perfusion technique, and in particular MTT maps, might be a very useful and noninvasive tool for evaluating hemodynamic status in MMS-NF1 patients.

Entities:  

Keywords:  MRI; Moyamoya; Neurofibromatosis type 1; SPECT

Mesh:

Year:  2020        PMID: 32651859      PMCID: PMC7843564          DOI: 10.1007/s10072-020-04574-4

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  41 in total

1.  Moyamoya syndrome in children with neurofibromatosis type 1: Italian-French experience.

Authors:  Claudia Santoro; Federico Di Rocco; Manoelle Kossorotoff; Michel Zerah; Nathalie Boddaert; Raphael Calmon; Dominique Vidaud; Mario Cirillo; Giuseppe Cinalli; Giuseppe Mirone; Teresa Giugliano; Giulio Piluso; Alessandra D'Amico; Valeria Capra; Marco Pavanello; Armando Cama; Bruno Nobili; Stanislas Lyonnet; Silverio Perrotta
Journal:  Am J Med Genet A       Date:  2017-04-19       Impact factor: 2.802

2.  Diagnosis of moyamoya disease on magnetic resonance imaging: are flow voids in the basal ganglia an essential criterion for definitive diagnosis?

Authors:  Takeshi Mikami; Toshiya Sugino; Shunya Ohtaki; Kiyohiro Houkin; Nobuhiro Mikuni
Journal:  J Stroke Cerebrovasc Dis       Date:  2012-08-29       Impact factor: 2.136

3.  Baseline Hemodynamic Impairment and Future Stroke Risk in Adult Idiopathic Moyamoya Phenomenon: Results of a Prospective Natural History Study.

Authors:  Colin P Derdeyn; Gregory J Zipfel; Allyson R Zazulia; Patricia H Davis; Shyam Prabhakaran; Cristina S Ivan; Venkatesh Aiyagari; James R Sagar; Nancy Hantler; Lina Shinawi; John J Lee; Hussain Jafri; Robert L Grubb; J Philip Miller; Ralph G Dacey
Journal:  Stroke       Date:  2017-03-10       Impact factor: 7.914

Review 4.  Cerebrovascular abnormalities in a population of children with neurofibromatosis type 1.

Authors:  Tena L Rosser; Gilbert Vezina; Roger J Packer
Journal:  Neurology       Date:  2005-02-08       Impact factor: 9.910

Review 5.  Moyamoya disease and moyamoya syndrome.

Authors:  R Michael Scott; Edward R Smith
Journal:  N Engl J Med       Date:  2009-03-19       Impact factor: 91.245

Review 6.  Cerebrovascular stenosis in neurofibromatosis type 1 and utility of magnetic resonance angiography: our experience and literature review.

Authors:  Felice D'Arco; Alessandra D'Amico; Ferdinando Caranci; Nilde Di Paolo; Daniela Melis; Arturo Brunetti
Journal:  Radiol Med       Date:  2013-12-03       Impact factor: 3.469

7.  Cerebral arteriopathy in children with neurofibromatosis type 1.

Authors:  David Rea; John F Brandsema; Derek Armstrong; Patricia C Parkin; Gabrielle deVeber; Daune MacGregor; William J Logan; Rand Askalan
Journal:  Pediatrics       Date:  2009-08-24       Impact factor: 7.124

8.  Neurofibromatosis type 1 association with moyamoya disease.

Authors:  Filiz Koc; Deniz Yerdelen; Zafer Koc
Journal:  Int J Neurosci       Date:  2008-08       Impact factor: 2.292

Review 9.  Moyamoya Syndrome: A Window of Moyamoya Disease.

Authors:  Ji Hoon Phi; Kyu-Chang Wang; Ji Yeoun Lee; Seung-Ki Kim
Journal:  J Korean Neurosurg Soc       Date:  2015-06-30

10.  Medullary unidentified bright objects in Neurofibromatosis type 1: a case series.

Authors:  Alessandra D'Amico; Federica Mazio; Lorenzo Ugga; Renato Cuocolo; Mario Cirillo; Claudia Santoro; Silverio Perrotta; Daniela Melis; Arturo Brunetti
Journal:  BMC Pediatr       Date:  2018-02-28       Impact factor: 2.125

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.